Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
Watch 5 AI-Powered Medical Stocks for a Strong Portfolio in 2026
08:45am, Monday, 05'th Jan 2026
LLY, MDT, ISRG, REGN and JNJ are five defensive medical stocks using AI to drive growth, diagnostics and innovation into 2026.
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Ascent Group LLC
04:06am, Sunday, 04'th Jan 2026
Ascent Group LLC decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 56.0% during the undefined quarter, according to the company in its most recent 13F filing with t
REGN Soars 41% in Six Months: Is There More Upside Potential in 2026?
09:40am, Friday, 02'nd Jan 2026
Regeneron shares are up 41% in six months as FDA approvals, strong Dupixent profits and oncology gains lift investor confidence.
Outlook Therapeutics Stock Sinks After FDA Rejects Eye Drug Again
08:18am, Friday, 02'nd Jan 2026
Outlook Therapeutics' stock fell to a new low due to FDA rejection of its Lytenava filing for wet AMD. Efficacy evidence remains key issue.
Perigon Wealth Management LLC Acquires 985 Shares of Regeneron Pharmaceuticals, Inc. $REGN
06:13am, Monday, 29'th Dec 2025
Perigon Wealth Management LLC grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 17.2% in the third quarter, according to its most recent filing with the Securities and Exchange Co
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of “Moderate Buy” by Brokerages
01:12am, Monday, 29'th Dec 2025
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the twenty-seven ratings firms that are covering the firm, Marketbeat re
Global X Japan Co. Ltd. Purchases 904 Shares of Regeneron Pharmaceuticals, Inc. $REGN
04:48am, Thursday, 25'th Dec 2025
Global X Japan Co. Ltd. grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 5,650.0% during the undefined quarter, according to its most recent filing with the Securities
ARS Investment Partners LLC Increases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN
03:19am, Thursday, 25'th Dec 2025
ARS Investment Partners LLC lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 37.9% during the third quarter, according to the company in its most recent filing with the Securit
Le Dupixent de Sanofi et Regeneron approuvé au Japon pour les enfants de 6 à 11 ans atteints d'asthme bronchique Approbation basée sur le programme mondial de phase 3 chez les enfants démontrant q
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
01:00am, Tuesday, 23'rd Dec 2025
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo
Press Release: Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma
01:00am, Tuesday, 23'rd Dec 2025
Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly reduce
Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
04:05pm, Monday, 22'nd Dec 2025
TARRYTOWN, N.Y., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January
Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Lifted by Osaic Holdings Inc.
05:18am, Sunday, 21'st Dec 2025
Osaic Holdings Inc. raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 55.2% in the second quarter, according to its most recent 13F filing with the Securities and Exch
Regeneron: The Turnaround Is Gaining Steam
09:30am, Saturday, 20'th Dec 2025
Regeneron Pharmaceuticals is poised for a turnaround as Eylea's patent cliff fades and new growth drivers emerge. Dupixent and Libtayo are expected to drive robust revenue and margin expansion, with D
Trump Secures Drug Price Cuts From 9 Major Pharma Firms Including Bristol Myers, Gilead, Merck In Medicaid Deal
01:38am, Saturday, 20'th Dec 2025
Trump and nine major pharmaceutical companies struck deals to lower drug prices for cash payers and Medicaid, with over $150 billion pledged for U.S. R&D and manufacturing.
